Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Translational & Preclinical Development

ChemPartner: Oncology Pharmacology

Read More
Translational & Preclinical Development

ChemPartner: Protein Sciences

Read More
Translational & Preclinical Development

ChemPartner: Cancer Cell Line Panel Screening

Leading Cell-Based Assay Service
Read More
Translational & Preclinical Development

ChemPartner: Cell Biology

Overview
Read More
Translational & Preclinical Development

Functional Evaluation of Unique Anti-PDL1 Antibodies Generated through Single Plasma B Cell Cloning on the Beacon® Platform Versus a Standard Hybridoma Approach

Read More
Translational & Preclinical Development

Crown Bioscience: Discover the Infinite Power of Partnership

We are Crown Bioscience and this is where Innovation and Quality Transforms Scientific Discovery
Read More
Translational & Preclinical Development

Evaxion Biotech Announce New Source of Immunotherapeutic Targets via AI Platform

ERVs have been strongly associated with overall survival in cancer patients. Evaxion hopes they can act as therapeutic targets for non-responsive immunotherapy patients.
Read More
Translational & Preclinical Development

Sensei Bio Presents Preclinical Data for Novel Antibody Therapeutic for Solid Tumours

Immuno-oncology company Sensei Bio gave a presentation which outlined convincing preclinical data for their novel antibody therapeutic.
Read More
Translational & Preclinical Development

AI-Guided Personalised Cancer Vaccine Designated Fast Track by FDA

Evaxion Biotech uses AI to personalise cancer vaccines for patients’ specific tumours.
Read More
Translational & Preclinical Development

Teon Tx and MSD Partner in Oral IO Clinical Trial

Teon Tx and MSD will partner to study a combination of a new immune-modifier and existing anti-PD-1 immune checkpoint inhibitor.
Read More
Translational & Preclinical Development

New Funding Given to Network of Experimental Cancer Medicine Centres

The ECMC network will enter new partnerships to increase the availability of clinical trials for cancer patients.
Read More
Translational & Preclinical Development

Approaches to Combinational Immunotherapies: From Clinic to Approval

Our panel discussing combination therapeutics addresses challenges, modelling, and the importance of biomarkers.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno